1. Introduction {#sec1-antibiotics-06-00036}
===============

Lower respiratory tract infection (LRTI) is the most common reason for consulting a general practitioner (GP) \[[@B1-antibiotics-06-00036],[@B2-antibiotics-06-00036]\]. LRTIs are often treated with antibiotics, even though this is not generally supported by guidelines and recommendations \[[@B2-antibiotics-06-00036],[@B3-antibiotics-06-00036],[@B4-antibiotics-06-00036],[@B5-antibiotics-06-00036],[@B6-antibiotics-06-00036]\]. Many trials and observational studies have found no or little benefit of antibiotic treatment for an acute cough \[[@B7-antibiotics-06-00036]\]. If an antibiotic is prescribed, amoxicillin is the recommended first-line treatment for LRTI \[[@B8-antibiotics-06-00036]\]. Amoxicillin is the most commonly used broad-spectrum penicillin accounting for an average 40% of the total outpatient antibiotic use in Europe \[[@B8-antibiotics-06-00036],[@B9-antibiotics-06-00036],[@B10-antibiotics-06-00036]\].

All medications have known adverse events (AEs) and antibiotics are no exceptions \[[@B11-antibiotics-06-00036]\]. Although most antibiotics are generally considered safe, and most AEs are moderate to mild, some antibiotics have been associated with life-threatening AEs \[[@B12-antibiotics-06-00036]\]. AEs are generally poorly reported in trials, and their true incidence is thought to be much higher than reported in trials \[[@B13-antibiotics-06-00036]\]. In primary care, a shared decision consultation should include both the benefits and potential harms of the (antibiotic) treatment prescribed \[[@B14-antibiotics-06-00036]\].

The European multicentre randomised placebo-controlled trial (RCT) of amoxicillin for LRTI in adults in primary care was performed by the GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe; <http://www.grace-lrti.org>) Network of Excellence. The GRACE trial identified significantly more AEs (diarrhoea or nausea or rash) in the amoxicillin group compared to the placebo group (AEs in week one and week two after antibiotic administration) \[[@B15-antibiotics-06-00036]\]. However, it was not clear whether this applies to each specific AE, or whether particular subgroups of patients suffer more AEs than others. To better inform primary care clinicians and their patients, this secondary analysis of the GRACE trial aims to provide estimates of any and each specific AE (diarrhoea, nausea, and rash) of amoxicillin, and identify subgroups of patients that are more at risk for any or a specific AE.

2. Results {#sec2-antibiotics-06-00036}
==========

2.1. Participant's Distribution by Subgroups {#sec2dot1-antibiotics-06-00036}
--------------------------------------------

A total of 2061 patients were recruited and randomly assigned to amoxicillin (1038) and to placebo (1023). Of the total, 595 (28%) were 60 years and older, 836 (40%) were males, 579 (28%) current smokers, and 470 (23%) reported symptoms of anxiety/depression on the day of consultation. Regarding the medication history, 283 (14%) had antibiotic treatment in previous 6 months, 1056 (51%) reported over-the-counter (OTC) treatment before consulting a general practitioner, 1342 (65%) were prescribed treatment other than study medication during their consultation. These other medications included 479 (23%) antihypertensive/diuretics, 201 (10%) oral bronchodilators, 171 (8%) steroids, 202 (10%) antidepressant/benzodiazepines, 174 (8%) non-steroidal anti-inflammatory drugs, and 451 (22%) influenza vaccines.

2.2. Subgroup Analysis of Adverse Events {#sec2dot2-antibiotics-06-00036}
----------------------------------------

For the whole cohort, at the end of week one, a significantly higher proportion of any AE (diarrhoea or nausea or rash) was reported in the amoxicillin group compared to placebo (OR = 1.31, 95% CI 1.05--1.64) ([Table 1](#antibiotics-06-00036-t001){ref-type="table"}). The number needed to harm (NNH) was 24, i.e., on average, for every 24 patients receiving amoxicillin, one additional patient had reported any AE due to the antibiotic at the end of week one. Any AE was reported significantly more often in patients ever being a smoker (OR = 1.41, 95% CI 1.04--1.90), and patients using OTC treatment before the consultation (OR = 1.44, 95% CI 1.09--1.91), but the interaction terms were not statistically significant. In patients with depression/anxiety on the day of consultation (OR = 1.49, 95% CI 0.99--2.22) and in those on any medication other than study medication (OR = 1.29, 95% CI 0.98--1.69) the odds ratios were borderline significant, but the interaction terms were not significant. This indicates that compared to the whole cohort, no subgroups were at higher risk of any AE (diarrhoea or nausea or rash) due to amoxicillin.

Analysing each specific AE, diarrhoea was present significantly more often among patients in the amoxicillin group, compared to those in the placebo group (OR 1.43 CI 1.08--1.90, [Table 2](#antibiotics-06-00036-t002){ref-type="table"}) (NNH: 29). Diarrhoea was significantly more often reported by patients 60 years and over (OR 1.97, 95% CI 1.09--3.54), current smokers (OR 2.07, 95% CI 1.15--3.76), ever being a smoker (OR 1.79, 95% CI 1.21--2.65), on OTC treatment before their consultation (OR 1.76 95% CI 1.23--2.53), and on antihypertensive/diuretics (OR 2.27, 95% CI 1.27--4.05). However, the interaction terms were not significant.

Nausea was not associated with amoxicillin treatment for either the whole cohort or any subgroup of patients ([Table 3](#antibiotics-06-00036-t003){ref-type="table"}). Rash was only significantly more often reported by males (interaction term 3.72, *p* = 0.021; odds ratio in males 2.79 (95% CI 1.08--7.22) ([Table 4](#antibiotics-06-00036-t004){ref-type="table"}).

3. Discussion {#sec3-antibiotics-06-00036}
=============

3.1. Summary {#sec3dot1-antibiotics-06-00036}
------------

To the authors' knowledge, this is the first subgroup analysis of any and specific AEs reported in RCTs of antibiotics for LRTI. Diarrhoea was significantly more likely to be reported in the amoxicillin group compared to the placebo group. No specific subgroups were at higher risk of any or a specific AE due to amoxicillin, apart from males in the amoxicillin group reporting rash significantly more often.

3.2. Strengths and Limitations {#sec3dot2-antibiotics-06-00036}
------------------------------

Our results are based on data from the largest RCT of antibiotics for acute LRTI in general practice to date \[[@B15-antibiotics-06-00036]\]. Its primary objective was not identifying the incidence of AEs. RCTs, such as the GRACE trial, are not always prospectively powered for subgroup analysis of AEs \[[@B16-antibiotics-06-00036]\]. Accordingly, subgroup analyses with multiple comparisons are often underpowered, with a greater risk of the false negative results (type II error). Large sample sizes are needed for robust subgroup analysis, which may only be possible by combining trial results in a meta-analysis \[[@B17-antibiotics-06-00036]\].

3.3. Comparison with Existing Literature {#sec3dot3-antibiotics-06-00036}
----------------------------------------

Reporting guidelines on RCTs indicate that more details on AEs of medication should be documented and reported to the concerned authority \[[@B18-antibiotics-06-00036]\]. However, AEs occurring during a trial are often underreported, in particular, when reporting results in trial publications. Underreporting may be a result of poor monitoring, missing data, or unclear case definitions \[[@B19-antibiotics-06-00036]\]. An important consequence of underreporting of AEs is a misinterpretation of the intervention's effects, particularly its harms \[[@B20-antibiotics-06-00036]\]. Although the GRACE trial captured AEs from the study medication, the reported AEs were limited to diarrhoea, nausea, and rash. A review paper identified that candidiasis was significantly associated with amoxicillin use \[[@B13-antibiotics-06-00036]\], and patients treated with amoxicillin were twice as likely, compared to placebo, to report diarrhoea \[[@B13-antibiotics-06-00036],[@B19-antibiotics-06-00036]\]. As in the previously published paper from GRACE trial \[[@B15-antibiotics-06-00036]\], the current study showed significantly more AEs (diarrhoea or nausea or rash) in amoxicillin group compared to placebo. The calculation of any AEs in the previous paper covered the first two weeks after the antibiotic was prescribed, however, this paper reports on any AEs in the first week while patients were taking antibiotics.

This study also showed a higher risk overall of diarrhoea in the amoxicillin group compared to the placebo group. Even though diarrhoea was more often reported in the treatment group for patients 60 years and older, smokers, patients taking OTC treatment before consulting a GP, patients on antihypertensive or non-steroidal anti-inflammatory drugs and those who received an influenza vaccine, no particular subgroup was at higher risk of AEs.

The presented analysis showed that males in the amoxicillin group reported rash significantly more often compared to males in the placebo group. Skin reactions were also associated with amoxicillin use \[[@B21-antibiotics-06-00036]\]. A borderline significant interaction term was observed for patients reporting anxiety/depression on the day of the consultation. These (borderline) significant results may be due to multiple testing, and with more conservative *p*-values, and these results would not be considered significant \[[@B22-antibiotics-06-00036]\]. Sensitivity analysis did not alter our conclusions.

4. Materials and Methods {#sec4-antibiotics-06-00036}
========================

4.1. Study Design and Patients {#sec4dot1-antibiotics-06-00036}
------------------------------

The GRACE trial was performed in 16 primary care research networks in 12 European countries. Details of the study design, patient inclusion, and recruitment were previously published \[[@B15-antibiotics-06-00036],[@B16-antibiotics-06-00036]\]. In summary, the study was conducted between November 2007 and April 2010, and recruited adult patients with LRTI that were randomly allocated to receive either 1 g of amoxicillin or placebo three times a day for 7 days.

4.2. Data Collection {#sec4dot2-antibiotics-06-00036}
--------------------

Data was collected using (a) a case record form (CRF), (b) a symptom diary, and (c) a short version of the diary. The latter was used to collect key outcome variables and AEs during a standardised phone call after 4 weeks, if participants had not returned their diary. For this subgroup analysis, we used information on antibiotic treatment in the previous six months, any medication during the study period, history of regular use of inhaled bronchodilators, steroids, antihypertensive/diuretics, benzodiazepines/antidepressant, oral non-steroidal anti-inflammatory drugs, or influenza vaccination recorded by the responsible clinician in the CRF. The symptom diary was completed by the patient every day from day one, i.e., day of consultation and inclusion, until resolution of symptoms, up to a maximum of 28 days. This diary has previously been validated, is sensitive to change, and internally reliable \[[@B23-antibiotics-06-00036]\]. Specific AEs, such as diarrhoea, nausea, and rash, were recorded at the end of week one and week two, and over-the-counter (OTC) treatment was recorded on day one. Anxiety and depression related questionnaires were completed by patients on the day of consultation (day one), and at the end of every week for four weeks. For the purpose of this study, we used anxiety and depression reported on day one. All information was collected blind to treatment allocation. All data collection forms were translated into relevant local languages and back-translated to ensure consistency.

4.3. Outcomes in the Study {#sec4dot3-antibiotics-06-00036}
--------------------------

The primary outcomes include the presence of specific AEs, diarrhoea, nausea, and rash. We also created another dichotomous outcome variable for the presence of "any reported AE" for those who had reported either diarrhoea or nausea or rash at the end of week one. Amoxicillin was administered for seven days in the study, and all AEs reported during week one were included in the primary outcome. Subsequent reported AEs was excluded from the analysis.

4.4. Sample Size Calculation {#sec4dot4-antibiotics-06-00036}
----------------------------

As this is a secondary analysis of previously collected data, sample size calculations are no longer relevant. Considering the proportion of any adverse events caused by amoxicillin \[[@B15-antibiotics-06-00036]\], a subgroup sample size of 136 patients allows detection of a 15% absolute difference in AEs (17.5% versus 2.5%, with 80% power, α = 0.05 (G\* power Version 3.1.9.2). Similarly, 302 patients would allow the detection of a 10% absolute difference. Analyses in smaller subgroups were considered underpowered, and were only reported for comprehensive purposes.

4.5. Statistical Analysis {#sec4dot5-antibiotics-06-00036}
-------------------------

The subgroup analyses of the AEs were not pre-specified. For any and each specific AE, we estimated the effect of amoxicillin using logistic regression analysis in Stata (version 13). Subgroup analyses were performed separately for any and each specific AE. The interaction between a particular subgroup (for example, males) and the intervention (in this case amoxicillin) concerns the difference in AEs (of amoxicillin) among the patients in that particular group (males), compared to patients who are not (females). The interaction term is the variable introduced into the statistical model to allow estimation of the size of that difference. The odds ratio in the subgroups estimates the difference in AEs between patients on amoxicillin and those on placebo. The specific subgroups were gender (male/female), age (60 years and older/less than 60 years), and yes/no groups for current and ever smoking, depression/anxiety on the day of the consultation, over-the-counter (OTC) treatment before consultation, antibiotics used in previous six months, use of any medication other than study medication, use of oral bronchodilators, on regular oral or inhaled steroids, on antihypertensive/diuretics, on antidepressant/benzodiazepams, on non-steroidal anti-inflammatory drugs and vaccinated against influenza. Sensitivity analysis was performed by recoding missing information on an AE as the absence of that AE.

4.6. Role of Funding Source {#sec4dot6-antibiotics-06-00036}
---------------------------

GRACE was funded by the European Commission's Framework Programme 6 (LSHM-CT-2005-518226). The work reported in this publication has been financially supported through TRACE (Translational Research on Antimicrobial resistance and Community-acquired infections in Europe; [www.esf.org/trace](www.esf.org/trace)). The researchers are independent of all funders.

4.7. Ethical Approval {#sec4dot7-antibiotics-06-00036}
---------------------

Ethical approval for the United Kingdom was granted by Southampton and South West Hampshire Local Research Ethics Committee (B) (ref. 07/H0504/104). Competent authority approval for the UK was granted by the Medicines and Healthcare Products Regulatory Agency. Ethical and competent authority approval was obtained from each local organisation at every research site outside of the UK. Patients who fulfilled the inclusion criteria were given written and verbal information, and informed consent was obtained before enrolment.

5. Conclusions {#sec5-antibiotics-06-00036}
==============

This subgroup analysis provides some evidence that the observed increased risk of any AE or diarrhoea due to amoxicillin was not specific, or more pronounced, in any subgroup of patients. In other words, all adult LRTI patients prescribed antibiotics are likely to be at the same risk for any AE or diarrhoea. We can reiterate the conclusion of the previous GRACE trial that the results do not suggest the use of amoxicillin where only little benefit has been observed for patients with uncomplicated LRTI in primary care. Before prescribing an antibiotic, their potential benefits and harms should be discussed with patients.

We are thankful to GRACE team for providing us with their data and the TRACE project for funding MT's work visit to the Department of Primary Care and Interdisciplinary Care of the University of Antwerp. We would like to acknowledge the dedication, expertise and enthusiasm of entire GRACE team and active participation of all patients.

M.T., A.V., and S.C. conceived of the secondary analysis of the GRACE database to explore AEs of amoxicillin. The protocol was approved by project coordinators H.G. and work packages leaders P.L., C.C.B., T.V., and M.T. performed the statistical analysis and drafted the paper. S.C. and R.B. supported the analysis. S.C. and A.V. helped writing and to shape the discussion. All authors contributed to the final manuscript and approved the final version.
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antibiotics-06-00036-t001_Table 1

###### 

Any adverse event (diarrhoea or nausea or rash) in the whole cohort, and in subgroups of adult patients in the first week after presenting to primary care with a LRTI and allocation to amoxicillin or placebo.

                                                  Amoxicillin   Placebo    Interaction Term (95% CI)   OR for Subgroups (95% CI)
  ----------------------------------------------- ------------- ---------- --------------------------- ---------------------------
  Whole cohort                                    219/1038      173/1023                               1.31 (1.05--1.64) \*
  Aged 60 years and older                         57/292        42/303     1.21 (0.72--2.00)           1.50 (0.97--2.33)
  Male                                            78/413        63/423     1.02 (0.64--1.62)           1.33 (0.92--1.91)
  Current smoking                                 60/307        38/272     1.18 (0.70--1.96)           1.49 (0.95--2.33)
  Ever being a smoker                             123/559       90/539     1.16 (0.74--1.81)           1.41 (1.04--1.90) \*
  Depression/anxiety on the day of consultation   77/231        60/239     1.17 (0.72--1.90)           1.49 (0.99--2.22)
  OTC treatment before consultation               152/535       112/521    1.28 (0.79--2.07)           1.44 (1.09--1.91) \*
  Antibiotic used in previous six months          26/143        27/140     0.66 (0.35--1.27)           0.93 (0.51--1.69)
  Any medication other than study medication      145/679       115/663    0.94 (0.59--1.51)           1.29 (0.98--1.69)
  Oral bronchodilators                            20/96         20/108     0.86 (0.41--1.79)           1.16 (0.57--2.31)
  On regular oral or inhaled steroids             17/84         18/87      0.71 (0.32--1.56)           0.97 (0.46--2.04)
  Antihypertensive/Diuretics                      52/239        43/240     0.95 (0.57--1.60)           1.27 (0.81--1.99)
  Antidepressant/benzodiazepams                   24/98         21/104     0.96 (0.48--1.96)           1.28 (0.65--2.49)
  Non-steroidal anti-inflamatory drugs            18/77         16/97      1.19 (0.54--2.61)           1.54 (0.72--3.27)
  Influenza vaccine                               42/226        31/225     1.10 (0.63--1.95)           1.43 (0.86--2.36)

\* Significant at *p*-value \< 0.05 and OTC = over-the-counter.

antibiotics-06-00036-t002_Table 2

###### 

Diarrhoea in the whole cohort and in subgroups of adult patients in the first week after presenting to primary care with a LRTI and allocation to amoxicillin or placebo.

                                                  Amoxicillin   Placebo   Interaction Term (95% CI)   OR for Subgroups (95% CI)
  ----------------------------------------------- ------------- --------- --------------------------- ---------------------------
  Whole cohort                                    129/1038      92/1023                               1.43 (1.08--1.90) \*
  Age 60 years and older                          33/242        20/270    1.50 (0.77--2.94)           1.97 (1.09--3.54) \*
  Male                                            49/335        37/343    0.94 (0.53--1.69)           1.42 (0.98--2.24)
  Current smoking                                 38/237        18/214    1.57 (0.79--3.11)           2.07 (1.15--3.76) \*
  Ever being a smoker                             76/443        46/443    1.54 (0.86--2.74)           1.79 (1.21 --2.65) \*
  Depression/anxiety on the day of consultation   39/224        32/239    0.89 (0.48--1.65)           1.36 (0.82--2.26)
  OTC treatment before consultation               91/523        55/516    1.63 (0.89--2.99)           1.76 (1.23--2.53) \*
  Antibiotics in previous six months              15/117        12/110    0.79 (0.33--1.88)           1.20 (0.53--2.69)
  Any medication other than study medication      82/551        63/544    0.75 (0.41--1.38)           1.33 (0.94--1.89)
  Oral bronchodilators                            12/82         10/89     0.91 (0.35--2.36)           1.35 (0.55--3.33)
  On regular oral or inhaled steroids \#          10/71         9/75      0.80 (0.29--2.21)           1.20 (0.46--3.16)
  Antihypertensive/Diuretics                      38/198        20/211    1.79 (0.92--3.49)           2.27 (1.27--4.05) \*
  Antidepressant/benzodiazepams                   13/81         8/87      1.32 (0.49--3.54)           1.89 (0.74--4.82)
  Non-steroidal anti-inflamatory drugs \#         13/60         4/81      4.02 (1.19--13.55) \*       5.32 (1.64--17.29) \*
  Influenza vaccine                               29/184        17/194    1.43 (0.70--2.92)           1.95 (1.03--3.68) \*

\* Significant at *p*-value \< 0.05 and OTC = over-the-counter; \# variables underpowered.

antibiotics-06-00036-t003_Table 3

###### 

Nausea in the whole cohort and in subgroups of adult patients in the first week after presenting to primary care with a LRTI and allocation to amoxicillin or placebo.

                                                  Amoxicillin   Placebo   Interaction Term (95% CI)   OR for Subgroups (95% CI)
  ----------------------------------------------- ------------- --------- --------------------------- ---------------------------
  Whole cohort                                    99/1038       82/1023                               1.21 (0.89--1.64)
  Age 60 years and older                          26/243        24/270    1.01 (0.51--2.02)           1.22 (0.68--2.20)
  Male                                            26/336        26/342    0.77 (0.39--1.52)           1.02 (0.58--1.79)
  Current smoking                                 25/237        20/213    0.90 (0.44--1.85)           1.14 (0.61--2.11)
  Ever being a smoker                             48/444        43/441    0.84 (0.45--1.56)           1.12 (0.73--1.73)
  Depression/anxiety on the day of consultation   37/224        31/237    0.09(0.57--2.09)            1.31 (0.78--2.20)
  OTC treatment before consultation               68/523        57/514    0.93 (0.47--1.82)           1.19 (0.82--1.74)
  Antibiotics in previous six months              14/117        13/110    0.80 (0.33--1.92)           1.01 (0.45--2.26)
  Any medication other than study medication      66/552        54/542    1.00 (0.52--1.93)           1.23 (0.84--1.79)
  Oral bronchodilators                            13/82         8/89      1.65 (0.61--4.45)           1.91 (0.75--4.87)
  On regular oral or inhaled steriods \#          10/71         9/75      0.98 (0.35--2.71)           1.20 (0.46--3.16)
  Antihypertensive/Diuretics                      21/198        20/211    0.91 (0.43--1.89)           1.13 (0.59--2.16)
  Antidepressant/benzodiazepams                   13/81         13/87     0.87 (0.35--2.14)           1.09 (0.47--2.51)
  Non-steroidal anti-inflamatory drugs \#         9/60          9/81      1.16 (0.41--3.30)           1.41 (0.52--3.80)
  Influenza vaccine                               18/185        14/194    1.17 (0.52--2.62)           1.38 (0.67--2.87)

\* Significant at *p*-value \< 0.05 and OTC = over-the-counter; \# variables underpowered.
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###### 

Rash in the whole cohort and in subgroups of adult patients in the first week after presenting to primary care with a LRTI and allocation to amoxicillin or placebo.

                                                  Amoxicillin   Placebo   Interaction Term (95% CI)   OR for Subgroups (95% CI)
  ----------------------------------------------- ------------- --------- --------------------------- ---------------------------
  Whole cohort                                    37/1038       33/1023                               1.11 (0.69--1.79)
  Age 60 years and older                          14/242        7/269     2.77 (0.93--8.23)           2.29 (0.91--5.79)
  Male                                            16/336        6/341     3.72 (1.22--11.36) \*       2.79 (1.08--7.22) \*
  Current smoking                                 8/237         5/213     1.36 (0.39--4.75)           1.45 (0.47--4.51)
  Ever being a smoker                             22/444        14/442    2.06 (0.78--5.46)           1.59 (0.80--3.16)
  Depression/anxiety on the day of consultation   19/224        11/238    2.44 (0.90--6.58)           1.91 (0.89--4.11)
  OTC treatment before consultation               25/522        25/514    0.64 (0.22--1.87)           0.98 (0.56--1.74)
  Antibiotics in previous six months              7/117         6/110     0.98 (0.28--3.42)           1.10 (0.36--3.39)
  Any medication other than study medication      25/551        20/543    1.33 (0.49--3.64)           1.24 (0.68--2.26)
  Oral bronchodilators                            2/81          4/89      0.45 (0.07--2.72)           0.54 (0.09--3.02)
  On regular oral or inhaled steriods \#          2/71          2/75      0.94 (0.12--7.32)           1.06 (0.14--7.72)
  Antihypertensive/Diuretics                      9/197         7/210     1.33 (0.42--4.17)           1.39 (0.50--3.80)
  Antidepressant/benzodiazepams                   6/80          6/87      0.96 (0.27--3.49)           1.09 (0.34--3.54)
  Non-steroidal anti-inflamatory drugs \#         2/60          6/81      0.34 (0.06--1.89)           0.43 (0.08--2.21)
  Influenza vaccine                               6/184         4/194     1.53 (0.38--6.11)           1.60 (0.44--5.77)

\* Significant at *p*-value \< 0.05 and OTC = over-the-counter; \# variables underpowered.
